|
Synonyms: ACE-910 | ACE910 | emicizumab-kxwh | Hemlibra® | RG6013
emicizumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Emicizumab, is a humanised bispecific antibody that binds blood coagulation factors IXa and X and acts as a factor VIII mimetic to bring about activation of factor X, and promote coagulation [2-3,5]. In essence, emicizumab works by bridging between coagulation factors IX and X and is the first-in-class drug for haemophilia A prevention with this mechanism of action.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Emicizumab was FDA approved in November 2017 as a routine prophylactic treatment for patients with factor VIII deficiency who have developed factor VIII-neutralising antibodies (inhibitors) in response to replacement factor VIII therapy [1]. See Phase 3 clinical trial NCT02622321 [4]. Emicizumab had EMA orphan medicinal product designation from January 2014-May 2017, for the management of haemophilia A, prior to marketing authorisation being granted in early 2018. In October 2018, FDA approval was expanded to permit treatment of hemophilia A patients regardless of factor VIII inhibitor status. In Japan, emicizumab is in Phase 3 trial as a potential treatment for the additional indication of acquired (autoimmune) hemophilia A [6]. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Emicizumab mimics the function of factor VIII to promote factor X activation and blood coagulation in patients with haemophilia A. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
